Jack has focused exclusively on the Medical Technology & Diagnostics sub-sectors since joining ICR Westwicke in early 2012, providing strategic advice and analysis for clients.
During his more than 10 year tenure at ICR Westwicke, Jack has worked with a variety of public and private clients, including Alliqua BioMedical, Apyx Medical Corporation, Avedro, Bovie Medical Corporation, ConforMIS, GreatBatch Medical, Hansen Medical, Helius Medical Technologies, Hologic, K2M Group Holdings, Lumenis, Organogenesis, Rochester Medical, Strand Life Sciences, Synergetics, Tactile Medical, Teleflex, Urologix, Venaxis and Venus Concept.
Jack advises clients on a variety of strategic and tactical IR-related subjects, helping them to establish ‘best-in-class’ practices and programs. He works closely with client senior leadership teams on the development of corporate earnings call scripts, Q&A prep. materials, press releases focused on the institutional investor audience, investor presentations, detailed financial models and analyst consensus models.
Jack also conducts data-driven analyses of trends in the MedTech sub-sector and the equity capital markets landscape (e.g., earnings-related disclosure, company announcements, IPOs & follow-on offerings) to help clients identify strategic and financial ‘best practices.’ He possesses a detailed knowledge of the institutional investment landscape, and provides clients with related insights as needed. Like many at ICR Westwicke, Jack approaches investor relations from the perspective of an institutional equity investor, having trained under a former T. Rowe Price equity analyst for his first 5 years at the firm.
Jack holds a B.A. in Economics from Connecticut College and lives in Baltimore, Maryland with his wife, Sophie.